Roche's Phase 3 Trial of Casirivimab, Imdevimab Shows Cut Risk of Symptomatic Covid-19 Infections

   By Mauro Orru 
 

Roche Holding AG said Monday that a Phase 3 trial involving casirivimab and imdevimab to cut risk of symptomatic Covid-19 infections yielded positive results, meeting primary and key secondary endpoints.

The Swiss pharmaceutical major said the trial showed the subcutaneous administration of casirivimab and imdevimab lowered risk of symptomatic Covid-19 infections by 81%.

Casirivimab and imdevimab also cut the overall risk of progressing to symptomatic Covid-19 by 31% in recently-infected asymptomatic patients.

"Although vaccinations are increasing globally, there remains a critical unmet need world-wide to prevent infections and provide immediate protection from Covid-19 between close contacts. This is why we are excited to bring this data to health authorities with the goal of making the combination available to more people as soon as possible," Roche's chief medical officer and head of global product development Levi Garraway said.

Roche said Regeneron Pharmaceuticals Inc. would share new data with the Food and Drug Administration in the U.S., with the two companies agreeing to cooperate with the European Medicines Agency and other health authorities.

Write to Mauro Orru at [e-mail]; @MauroOrru94

(END) Dow Jones Newswires

April 12, 2021 01:37 ET (05:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.